Cutaneous Leishmaniasis (L. major): Systemic Treatment After Local Therapy Has Failed to Achieve Healing

This protocol covers cutaneous leishmaniasis caused by Leishmania major when the local treatment approach has not achieved full lesion healing, or when the lesion extent or location makes systemic management the appropriate choice from the outset.

Clinical Scenario

The patient has cutaneous leishmaniasis caused by Leishmania major — presenting with more than three lesions, a lesion diameter exceeding 30 mm, involvement of a delicate anatomical location, or confirmed failure to respond to local treatment.

Previous Treatment Line — Failure Condition

Initial local treatment — including cryotherapy with local antimonial infiltration, topical paromomycin- or methylbenzethonium chloride-based ointment, or local heat therapy — was attempted for limited disease (up to three lesions, diameters below 30 mm). The required outcome, complete reepithelialization of the cutaneous lesion, was not achieved. This failure to heal is the condition that advances management to the systemic line described here.

Treatment Goal

The primary clinical endpoint is complete reepithelialization — full healing — of the cutaneous lesion.

Treatment Approach (Partial Overview)

At this stage, management moves to systemic therapy. More than one systemic option is recognized for this scenario; the choice depends on lesion characteristics and patient factors. The full structured regimen — including options, criteria for selection, and sequencing — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Treatment of L. major
1. Miltefosine (50 mg tid × 28 days) [B]
2. Fluconazole (200 mg bid × 6 weeks) [C]
3. Liposomal amphotericin B (18 mg/kg total dose: 3 mg/kg/day, days 1 to 5 and at day 10) [D]
4. Systemic pentavalent antimonial (Sb 20 mg/kg) and pentoxifylline (3 × 400 mg/20 days) [A] or systemic pentavalent antimonial (Sb 20 mg/kg for 10–20 days) [D]
Treatment failure is present when reepithelialization is incomplete 3 months after starting therapy.

DOI: 10.1111/jtm.12089

View source ↗